Prediction of chemotherapy benefit by EndoPredict® Breast Cancer Prognostic Test

Download the clinical summary

Which patients with ER positive/HER2 negative breast cancer will benefit from chemotherapy? EndoPredict provides 10 years’ personalized chemobenefit for every patient to guide decision-making.

Prediction of chemotherapy benefit by EndoPredict was shown in a large cross-cohort study with over 3,700 pre- and postmenopausal patients with ER positive/HER2 negative, node positive and node negative breast cancer.

Fill out the form below to download your free copy of the clinical summary to learn more about this key study.

Premenopausal clinical summary front cover image